At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 34 enrolled
Drug / intervention
Imatinib mesylate +1 moredrug
Likely dose
Imatinib mesylate 600 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Intermittent Gleevec® (Imatinib Mesylate) and Weekly Paclitaxel in Patients Aged 70 or Older With Advanced Non-small Cell Lung Cancer
In Brief
A Phase 2 clinical trial evaluating Imatinib mesylate and Paclitaxel for Non-small Cell Lung Cancer. Completed, enrolled 34 participants across 3 sites.
Detailed Summary
This study will evaluate the clinical efficacy of combining Gleevec (imatinib mesylate), a PDGFR antagonist, with front-line, single-agent paclitaxel in a cohort of elderly patients with advanced, non-small cell lung cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-small Cell Lung Cancer
CountriesUnited States
CollaboratorsFred Hutchinson Cancer Center, Novartis
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartAug 2009
First PostedNov 2009
Primary CompletionJul 2011
Study CompletionJul 2012
TodayJul 2026
First PostedNov 11, 2009
Enrollment StartAug 1, 2009
Primary CompletionJul 1, 2011
Study CompletionJul 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 16.6 years ago
Interventions
Imatinib mesylatedrug
Imatinib (Gleevec) 600 mg/day, oral administration in 4-day pulses(days 1-4; 8-11; 15-18) Cycle length: 28 days Number of cycles: up to 6
Paclitaxeldrug
Paclitaxel 90 mg/m2 IV on days 3, 10, 17 Cycle length: 28 days Number of cycles: up to 6